Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Clinical trial NCT04530123 · COMPLETED
Trial details
- NCT number
- NCT04530123
- Sponsor
- Takeda
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-23
- Primary completion
- 2025-12-09
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.